A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

  • Frentzas, Sophia (Primary Chief Investigator (PCI))
  • Webber, Kate (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description


StatusActive
Effective start/end date21/03/22 → 15/03/27

Keywords

  • phase 3 study
  • endometrial cancer
  • treatment safety
  • treatment efficacy